Masimo Newsroom

Wells Fargo Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $160

Moomoo News05:33 ET

Buy Rating Affirmed: Masimo's Legal Stability and Growth Prospects Fuel Optimism

TipRanks04:56 ET

Masimo Analyst Ratings

BenzingaJul 9 11:49 ET

Masimo (MASI) Receives a Hold From Needham

TipRanksJul 9 11:22 ET

Masimo's Strategic Divestiture and Joint Venture Prospects Bolster Buy Rating

TipRanksJul 9 05:32 ET

Masimo Analyst Ratings

BenzingaJun 3 08:31 ET

Piper Sandler Upgrades Masimo to Overweight, Price Target at $160

MT NewswiresJun 3 07:27 ET

Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $126

BenzingaMay 8 08:16 ET

Piper Sandler Keeps Their Hold Rating on Masimo (MASI)

TipRanksMay 8 07:42 ET

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)

TipRanksMay 8 07:10 ET

Masimo Analyst Ratings

BenzingaMay 8 06:41 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Masimo (MASI), Halozyme (HALO) and McKesson (MCK)

TipRanksMay 8 06:25 ET

Buy Rating Affirmed for Masimo Amidst Stable Financials and Strategic Business Optimism

TipRanksApr 25 07:31 ET

Stifel Upgrades Masimo to Buy, Sees Room for Share Price Appreciation

Seeking AlphaApr 15 14:36 ET

Masimo Analyst Ratings

BenzingaApr 15 06:32 ET

Buy Rating Affirmed for Masimo: Strategic Developments and Positive Outlook Signal Growth

TipRanksApr 15 05:01 ET

Buy Rating Affirmed for Masimo Amid Strategic Split and Enhanced Profitability Outlook

TipRanksApr 2 05:12 ET

Wells Fargo Upgrades Masimo to Overweight, Cites Spinoff Plan

Seeking AlphaMar 25 14:48 ET

Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)

TipRanksMar 25 06:50 ET

Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Masimo (MASI)

TipRanksMar 25 05:35 ET